Oshiro Noriko, Takahashi Rinako, Yoshino Ken-ichi, Tanimura Keiko, Nakashima Akio, Eguchi Satoshi, Miyamoto Takafumi, Hara Kenta, Takehana Kenji, Avruch Joseph, Kikkawa Ushio, Yonezawa Kazuyoshi
Biosignal Research Center, Kobe University, Kobe 657-8501, Japan.
J Biol Chem. 2007 Jul 13;282(28):20329-39. doi: 10.1074/jbc.M702636200. Epub 2007 May 21.
The proline-rich Akt substrate of 40 kilodaltons (PRAS40) was identified as a raptor-binding protein that is phosphorylated directly by mammalian target of rapamycin (mTOR) complex 1 (mTORC1) but not mTORC2 in vitro, predominantly at PRAS40 (Ser(183)). The binding of S6K1 and 4E-BP1 to raptor requires a TOR signaling (TOS) motif, which contains an essential Phe followed by four alternating acidic and small hydrophobic amino acids. PRAS40 binding to raptor was severely inhibited by mutation of PRAS40 (Phe(129) to Ala). Immediately carboxyl-terminal to Phe(129) are two small hydrophobic amino acid followed by two acidic residues. PRAS40 binding to raptor was also abolished by mutation of the major mTORC1 phosphorylation site, Ser(183), to Asp. PRAS40 (Ser(183)) was phosphorylated in intact cells; this phosphorylation was inhibited by rapamycin, by 2-deoxyglucose, and by overexpression of the tuberous sclerosis complex heterodimer. PRAS40 (Ser(183)) phosphorylation was also inhibited reversibly by withdrawal of all or of only the branched chain amino acids; this inhibition was reversed by overexpression of the Rheb GTPase. Overexpressed PRAS40 suppressed the phosphorylation of S6K1 and 4E-BP1 at their rapamycin-sensitive phosphorylation sites, and reciprocally, overexpression of S6K1 or 4E-BP1 suppressed phosphorylation of PRAS40 (Ser(183)) and its binding to raptor. RNA interference-induced depletion of PRAS40 enhanced the amino acid-stimulated phosphorylation of both S6K1 and 4E-BP1. These results establish PRAS40 as a physiological mTORC1 substrate that contains a variant TOS motif. Moreover, they indicate that the ability of raptor to bind endogenous substrates is limiting for the activity of mTORC1 in vivo and is therefore a potential locus of regulation.
富含脯氨酸的40千道尔顿Akt底物(PRAS40)被鉴定为一种与 Raptor结合的蛋白,在体外它可被雷帕霉素哺乳动物靶标(mTOR)复合物1(mTORC1)直接磷酸化,但不能被mTORC2磷酸化,主要磷酸化位点在PRAS40的Ser(183)。S6K1和4E-BP1与Raptor的结合需要一个TOR信号(TOS)基序,该基序包含一个必需的苯丙氨酸,其后是四个交替的酸性和小的疏水氨基酸。PRAS40(Phe(129)突变为Ala)的突变严重抑制了PRAS40与Raptor的结合。在Phe(129)的紧邻羧基末端是两个小的疏水氨基酸,其后是两个酸性残基。主要mTORC1磷酸化位点Ser(183)突变为Asp也消除了PRAS40与Raptor的结合。PRAS40(Ser(183))在完整细胞中被磷酸化;这种磷酸化被雷帕霉素、2-脱氧葡萄糖以及结节性硬化复合物异二聚体的过表达所抑制。PRAS40(Ser(183))的磷酸化也可通过去除所有或仅去除支链氨基酸而被可逆性抑制;这种抑制可通过Rheb GTP酶的过表达而逆转。过表达的PRAS40抑制了S6K1和4E-BP1在其对雷帕霉素敏感的磷酸化位点的磷酸化,相反,S6K1或4E-BP1的过表达抑制了PRAS40(Ser(183))的磷酸化及其与Raptor的结合。RNA干扰诱导的PRAS40缺失增强了氨基酸刺激的S6K1和4E-BP1的磷酸化。这些结果确立了PRAS40作为一种含有变异TOS基序的生理性mTORC1底物。此外,它们表明Raptor结合内源性底物的能力在体内限制了mTORC1的活性,因此是一个潜在的调控位点。